British and U.S. researchers said they had grown a crystal that enabled them to see the structure of an enzyme called integrase, which is found in retroviruses like HIV and is a target for some of the newest HIV medicines.
“Despite initially painstakingly slow progress and very many failed attempts, we did not give up and our effort was finally rewarded,” said Peter Cherepanov of Imperial College London, who conducted the research with scientists from Harvard University.
The Imperial and Harvard scientists said that having the integrase structure means researchers can begin fully to understand how integrase inhibitor drugs work, how they might be improved, and how to stop HIV developing resistance to them.
When the human immunodeficiency virus (HIV) infects someone, it uses the integrase enzyme to paste a copy of its genetic information into their DNA, Cherepanov explained in the study published in the Nature journal on Sunday.
Some new drugs for HIV — like Isentress from Merck & Co and elvitegravir, an experimental drug from Gilead Sciences — work by blocking integrase, but scientists are not clear exactly how they work or how to improve them.
The only way to find out was to obtain high-quality crystals — a project that had defeated scientists for many years.
Doug
CDIstaffing.com
